# Altos Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altos-biologics

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.altosbiologics.com/
- Total disclosed funding: $73M
- Latest round: Series B (Jul 9, 2024)
- Investors on record: 8

## About

Based in South Korea, Altos Biologics operates in the biotechnology sector, focusing on innovative solutions to tackle significant health challenges through the development of biologics for therapeutic applications.Altos Biologics, founded in 2020 and headquartered in Daejeon, South Korea, specializes in biotechnological solutions aimed at addressing critical health issues. The company has successfully completed 3 deals, with the latest being a Series B funding round on July 9, 2024, raising KRW 24.5 billion from investors including Industrial Bank of Korea, Magna Investment, Smart & Growth, and Solidus Investment. The founder's history is not publicly documented, and there are no known subsidiaries or parent companies associated with Altos Biologics.ALTOS Biologics specializes in biotechnological solutions aimed at addressing critical health challenges. The company offers a range of services, including the development and delivery of biologics tailored for therapeutic applications. These products function to enhance patient outcomes in various medical fields, including oncology and immunology, effectively targeting specific health issues through innovative biologic agents. ALTOS Biologics serves a diverse clientele that encompasses healthcare providers, research institutions, and pharmaceutical companies, primarily in the Asian markets, including but not limited to South Korea, Japan, and China. The company's commitment to innovation is reflected in its continuous pipeline of product development, aimed at creating impactful health solutions designed to meet the evolving needs of patients and healthcare systems.ALTOS Biologics generates revenue through a structured model that includes B2B partnerships and direct service offerings to healthcare providers and institutions. The company's revenue streams are primarily derived from biopharmaceutical product sales and ongoing service contracts, which facilitate access to their advanced biologic therapies. Transactions typically involve long-term agreements with hospitals and clinics, where ALTOS provides tailored biologic solutions based on specific clinical needs. The pricing structure for these services is designed to reflect the complexity and innovation of their product offerings, aligning costs with the value delivered to healthcare professionals and end patients. This transactional framework supports the sustainable growth of the company and strengthens its position within the competitive biotechnology landscape.In July 2024, Altos Biologics raised KRW 24.5 billion in Series B funding to advance its product development, particularly focusing on OP-01, a multi-antibody treatment for eye diseases. The company plans to utilize this funding to enhance its research capabilities and accelerate the development of OP-01, with a view to launching it in the near future. Additionally, Altos Biologics aims to expand its reach into new markets, specifically targeting regions in Asia beyond South Korea, including Japan and China, by the end of 2025.

## Funding rounds

- Series B, Jul 9, 2024, $18M — Industrial Bank of Korea, Solidus Investment, Magna Investment, Smart & Growth
- Series A, Jan 15, 2021, $46M — Solidus Investment, SJ Investment Partners, Hanlim Pharm. Co., Ltd., DS Asset Management
- Series A, Dec 16, 2020, $9.1M — G.N.TECH Venture Capital, Magna Investment

## Investors

- G.N.TECH Venture Capital (https://capitalatlas.ai/funds/g-n-tech-venture-capital) — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A, Series B
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series A, Series B
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A
- Hanlim Pharm. Co., Ltd. — Series A
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series A
- Industrial Bank of Korea — Series B
- Smart & Growth (https://capitalatlas.ai/funds/smart-growth) — Series B